Fundraising Fox

Myeloid Therapeutics

4 known investors

myeloidtx.com ↗

CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis. The company's multi-immune platform enables off-the-shelf therapies with repeat dosing capability.

AI & Machine LearningBiotechHealthtechMedical Devicesin /createmedicines@CREATEMedicines

Investors · 4

ARCH Venture PartnersChicago · $50K – $250M
8VCreportedAustin · $100K – $50M
Hatteras Venture Partnersreported · 2 sourcesResearch Triangle · $500K – $4M
Newpath PartnersreportedBoston · $50K – $10M

In the news